Hitting the brakes: targeting microtubule motors in cancer

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Cytotoxic chemotherapy remains crucial for cancer treatment, often targeting rapidly dividing tumor cells.
• Microtubule-targeting agents, while effective against mitosis, cause significant neurotoxicity due to essential neuronal functions.
• Developing more specific anti-mitotic drugs is a key goal to improve therapeutic index.

Purpose of the Study:

• To review lessons learned from antimitotic therapies, particularly inhibitors of microtubule motor proteins.
• To identify novel, tumor-specific cytotoxic targets based on cancer genome data.
• To enhance cancer specificity and reduce dose-limiting toxicities of chemotherapeutic agents.

Main Methods:

• Literature review of antimitotic therapies and microtubule motor protein inhibitors.
• Analysis of cancer genome data to identify tumor type-specific alterations in motor proteins.
• Evaluation of potential of motor proteins as novel cytotoxic targets.

Main Results:

• Antimitotic therapies targeting microtubules have yielded valuable insights but face challenges with neurotoxicity.
• Microtubule motor proteins represent a class of targets with potential for increased cancer specificity.
• Cancer genome data reveals tumor-specific alterations in several motor proteins warranting further investigation.

Conclusions:

• Targeting microtubule motor proteins offers a promising strategy to develop more specific anti-cancer drugs.
• Further research into tumor-specific motor protein alterations could lead to novel, less toxic chemotherapies.
• Optimizing antimitotic therapies requires a focus on targets with enhanced cancer specificity.